Hanall Biopharma, Stock Price -0.71% at This Time... 'From Argenx to the Second Half of the Year'

HanAll BioPharma is trading at 27,900 KRW as of 10:30 AM on the 28th, down 0.71% from the previous day. The trading volume is 397,318 shares, which is 8.53% of the previous day's volume. HanAll BioPharma is known as an R&D-focused pharmaceutical and bio company.

On May 27, Jaekyung Park, a researcher at Hi Investment & Securities, stated, "Argenx (NASDAQ: ARGX) ARGX-113 myasthenia gravis topline results announcement led to a 34.29% increase. Primary endpoint met (p ≤ 0.0001), no safety issues. BLA submission planned by the end of this year. MG phase 2 results to be announced in August, wAIHA phase 2 results expected in December. Possible entry into MG phase 3 within this year if early. HL161 also shows excellent IgG reduction ability and safety (no headache side effects), so the MG phase 2 announced in August is also judged to have a high possibility of success." He set the target price for HanAll BioPharma at 37,000 KRW.

Over the past five days, individual investors have net sold 30,609 shares of HanAll BioPharma, while foreigners and institutions have net sold 114,862 shares and net bought 306,668 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.